Loading…
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-98M | $-87M | $-82M | -23.6% | - | 40.5% |
| 2024 | $0M | $-68M | $-62M | $-56M | -24.1% | - | 90.2% |
| 2023 | $0M | $-35M | $-33M | $-32M | 44.9% | - | 24.6% |
| 2022 | $0M | $-26M | $-26M | $-24M | 61.3% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 |
| Operating Revenue | 0 | 0 | 0 | 0 |
| Operating Expense | 25.16 | 35.31 | 68.19 | 98.06 |
| Research And Development | 21.40 | 28.53 | 57.42 | 79.16 |
| Selling General And Administration | 3.76 | 6.78 | 10.78 | 18.90 |
| Total Expenses | 25.16 | 35.31 | 68.19 | 98.06 |
| Operating Income | -25.16 | -35.31 | -68.19 | -98.06 |
| Total Operating Income As Reported | -25.16 | -35.31 | -68.19 | -98.06 |
| EBITDA | -25.70 | -35.15 | -67.95 | -97.81 |
| Normalized EBITDA | -24.73 | -35.15 | -67.95 | -97.81 |
| EBIT | -25.76 | -35.31 | -68.19 | -98.06 |
| Interest Income | 0.37 | 2.75 | 6.27 | 11.08 |
| Interest Expense | 0.37 | 0 | - | - |
| Net Interest Income | 0 | 2.75 | 6.27 | 11.08 |
| Other Income Expense | -0.97 | - | - | - |
| Interest Income Non Operating | 0.37 | 2.75 | 6.27 | 11.08 |
| Interest Expense Non Operating | 0.37 | 0 | - | - |
| Net Non Operating Interest Income Expense | 0 | 2.75 | 6.27 | 11.08 |
| Pretax Income | -26.14 | -32.56 | -61.92 | -86.97 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | -26.14 | -32.56 | -61.92 | -86.97 |
| Net Income From Continuing And Discontinued Operation | -26.14 | -32.56 | -61.92 | -86.97 |
| Net Income From Continuing Operation Net Minority Interest | -26.14 | -32.56 | -61.92 | -86.97 |
| Net Income | -26.14 | -32.56 | -61.92 | -86.97 |
| Net Income Common Stockholders | -26.14 | -32.56 | -61.92 | -86.97 |
| Net Income Including Noncontrolling Interests | -26.14 | -32.56 | -61.92 | -86.97 |
| Normalized Income | -25.16 | -32.56 | -61.92 | -86.97 |
| Diluted NI Availto Com Stockholders | -26.14 | -32.56 | -61.92 | -86.97 |
| Basic Average Shares | 31.85 | 31.85 | 10.64 | - |
| Diluted Average Shares | 31.85 | 31.85 | 10.64 | - |
| Reconciled Depreciation | 0.06 | 0.16 | 0.24 | 0.25 |
| Total Unusual Items | -0.97 | 0 | - | - |
| Total Unusual Items Excluding Goodwill | -0.97 | 0 | - | - |
| Special Income Charges | -0.90 | 0 | - | - |
| Other Special Charges | 0.90 | - | - | - |
| Gain On Sale Of Security | -0.07 | - | - | - |
| General And Administrative Expense | 3.76 | 6.78 | 10.78 | 18.90 |
| Other Gand A | 3.76 | 6.78 | 10.78 | 18.90 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| MBX Biosciences, Inc.this co. | MBX | $1.5B | -16.92 | 3.98 | -23.6% | -14.28 |
| AnaptysBio, Inc. | ANAB | $1.5B | - | 40.41 | -35.6% | 17.42 |
| STAAR Surgical Company | STAA | $1.5B | -18.48 | 4.32 | -23.4% | -36.86 |
| Perrigo Company plc | PRGO | $1.5B | -1.04 | 0.50 | -48.6% | -5.75 |
| NeoGenomics, Inc. | NEO | $1.5B | -13.63 |
| 1.76 |
| -12.9% |
| -44.52 |
| Monte Rosa Therapeutics, Inc. | GLUE | $1.5B | -37.97 | 6.29 | -16.6% | -30.01 |
| Aveanna Healthcare Holdings Inc. | AVAH | $1.4B | 6.42 | 7.40 | 115.3% | 10.26 |
| Septerna, Inc. | SEPN | $1.4B | -28.93 | 3.70 | -12.8% | -16.63 |
| Maze Therapeutics, Inc. | MAZE | $1.4B | -10.72 | 3.96 | -36.9% | -8.82 |
| Peer Median | - | -13.63 | 4.14 | -20.0% | -12.73 | |